Procedures Completed in Various Spine & Pain Centers of Excellence Throughout ... care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical's financial advisor is Morgan Stanley & Co. LLC and Wyrick Robbins Yates & Ponton LLP is serving as legal ...

Patients can now receive interventional techniques that are no longer palliative in nature,” stated Samir Khan, DO, provider ...

Dr Jocelyn Fitzgerald, who specializes in disorders of the pelvic floor, is ‘begging women to learn’ the physical risks and ...

Needham reiterated a Hold rating on Globus Medical (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an impressive revenue growth of 102% over the last twelve ...

Arthritis, which refers to joint inflammation and degradation, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, is one of the most common causes of pain ...

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

Nov. 13, 2024 — A new study by medicine safety experts found the use of gabapentinoids -- medicines widely used to treat neuropathic pain -- increased the risk of hip fractures, especially in ...